As a 501(c)(3) nonprofit, we depend almost entirely on donations from people like you.
We really need your help to continue this work! Please consider making a donation.
Subscribe here and join over 13,000 subscribers to our free weekly newsletter

Drug label information not enough
Key Excerpts from Article on Website of MSNBC/Associated Press

MSNBC/Associated Press, October 21, 2009
Posted: October 29th, 2009

Did you know that Lunesta will help you fall asleep just 15 minutes faster? Or that a higher dose of the osteoporosis drug Zometa could damage a cancer patients kidneys and raise their risk of death? Chances are you didnt, and neither did your doctor. Much of what the Food and Drug Administration knows about a drugs safety and effectiveness is not included on the label, say two drug safety experts who are calling on the agency to make that information more accessible. In ... the New England Journal of Medicine, researchers ... argue that drug labels dont reflect the nuanced decisions the FDA makes when deciding to approve a drug. The editorial from Drs. Lisa Schwartz and Steven Woloshin recommends easy-to-read fact boxes to help patients weigh the benefits and risks of medications. If drug labels sometimes exaggerate benefits and play down drug risks, the authors say theres a very good reason: they are written by drugmakers. While FDA must approve the final labeling, the actual language is drafted by the manufacturer, with input from FDA scientists. The labeling is based on results from company studies, which generally compare results for patients taking the drug versus those taking placebo. If FDA decides the drugs ability to treat or prevent a disease outweighs its side effects, the agency is obligated to approve it. But Schwartz and Woloshin point out that benefits may be slim and potential harms may not be fully understood. The take home point is that just because a drug is approved doesnt mean it works very well, said Schwartz, in an interview with the Associated Press. You really need to know more to see whether its worth the cost. Schwartz and Woloshin say FDA labeling frequently fails to provide a full picture of a drugs effects.

Note: For a powerful summary of corruption in the pharmaceutical industry, click here.

Latest News

Key News Articles from Years Past